Veristat supports the battle against rare cancers by participating in the Cycle for Survival

By JoAnn Eckhoff

Veristat employees join together to help fund research to develop new and better treatments for rare cancers

Veristat  team members rode in the Cycle for Survival on February 7, 2015 in support of cancer research.

According to the National Institutes of Health (NIH), a "rare cancer" is one with a prevalence of fewer than 200,000 affected individuals in the United States. However, combining all rare cancer types together, they account for approximately half of all cancer diagnoses. Research on many rare cancers is drastically underfunded, often leaving patients with limited or no treatment options.

Cycle for Survival is high-energy indoor team cycling events that provide a tangible, fun and empowering way to fight cancer. Within six months of each event, 100% of the funds raised directly support rare cancer research at Memorial Sloan Kettering Cancer Center. Over $61.2 million has been raised through the event to date and the funds have directly contributed to 100+ clinical trials and research studies.

Patrick Flanagan, Chief Executive Officer of Veristat remarked, “Veristat elected to participate in this event as an ongoing commitment to support the campaign to defeat cancer. Veristat is riding in Cycle for Survival on behalf of family, friends, and colleagues who have felt the negative impact of this terrible disease. We are an active fighter in the battle against cancer.”

About Veristat

Veristat, Inc. is an innovative, science-focused clinical research organization (CRO) in its 20th year of providing expertise in supporting clinical trials and regulatory submissions for pharmaceutical, biotechnology, and medical device companies. Veristat offers comprehensive clinical development services, including biostatistics, statistical programming, medical writing, clinical monitoring and data management, for a single study or an entire clinical program, as well as preparation of integrated summary documents and submission-ready CDISC data for regulatory filings. Due to Veristat’s unwavering commitment to scientific integrity, client focus and exceptional performance, long-lasting client relationships are our hallmark.